MENU
+Compare
IRD
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$1.13
Change
-$0.03 (-2.59%)
Capitalization
35.67M

IRD Opus Genetics Inc Forecast, Technical & Fundamental Analysis

a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics

Industry Biotechnology
IRD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for IRD with price predictions
Jan 08, 2025

IRD's RSI Oscillator is sitting in overbought zone for 3 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

IRD broke above its upper Bollinger Band on January 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 27, 2024. You may want to consider a long position or call options on IRD as a result. In of 114 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IRD just turned positive on December 26, 2024. Looking at past instances where IRD's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

IRD moved above its 50-day moving average on December 27, 2024 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IRD crossed bullishly above the 50-day moving average on January 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where IRD advanced for three days, in of 264 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.040) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.853). IRD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (3.355) is also within normal values, averaging (264.084).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IRD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
IRD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BILI17.470.49
+2.89%
Bilibili
CSGP73.850.43
+0.59%
CoStar Group
CNNE19.06-0.11
-0.57%
Cannae Holdings
MULN0.48N/A
-0.73%
Mullen Automotive Inc
EDAP2.17-0.03
-1.36%
EDAP TMS SA

IRD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IRD has been loosely correlated with ARRY. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if IRD jumps, then ARRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IRD
1D Price
Change %
IRD100%
-2.59%
ARRY - IRD
35%
Loosely correlated
-0.14%
OABI - IRD
32%
Poorly correlated
+0.94%
MURA - IRD
32%
Poorly correlated
+8.40%
NTLA - IRD
31%
Poorly correlated
+0.85%
VIR - IRD
31%
Poorly correlated
+0.60%
More